tanruprubart

Monoclonal antibody

Filedsubmitted

Evidence outlook · regulatory review

Guillain-Barré Syndrome: application submitted to EMA

Marketing authorisation application submitted to the EMA for tanruprubart in Guillain-Barré syndrome (2026-01-08). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Latest reported trial: NCT04701164 · Phase 3 · met primary endpoint · grade pending

Also in development:Huntington's Disease · Phase 2

Source for the program status

Company guidance: data expected second half of 2026 (Annexon, Inc., 12 Aug 2026). “The currently ongoing open-label FORWARD study in the U.S. and Europe, which is designed to broaden Western experience with tanruprubart, and we anticipate initial PK, PD, biomarker and functional data in the second half of 2026 to supplement our comprehensive data package for tanruprubart in GBS.” Source ↗

Company guidance: regulatory filing expected Q4 2026 (Annexon, Inc., 9 Nov 2026). “Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026; Tanruprubart EU MAA Currently Under Review” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Guillain-Barré Syndrome
Phase 2 (3)
Huntington's Disease
Other / comorbidity
NCT04569435 · Annexon, Inc.
2021-01-15 – 2024-04-23 · Amyotrophic Lateral Sclerosis
What this study did
NCT04691570 · Annexon, Inc.
2021-11-10 – 2023-01-17 · Warm Autoimmune Hemolytic Anemia (wAIHA)
What this study did
Phase 1 (2)
Guillain-Barré Syndrome
NCT04035135 · Annexon, Inc.
2020-01-29 – 2021-05-19 · Guillain-Barré Syndrome
What this study did
Other / comorbidity
NCT03010046 · Annexon, Inc.
2016-12 – 2018-06 · Safety and Tolerability in Healthy Volunteers
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Huntington's Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tanruprubart: this drugPhase 2Monoclonal antibodyComplement C1qnot yet gradedNo reviewed efficacy summary in this indication
Valbenazine (Ingrezza)ApprovedSmall moleculevesicular monoamine transporter 2 (VMAT2)Partial signal
NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD).
Vonaprument
Phase 3(overall)
Antibody fragmentComplement C1q
Partial signal(overall)
No reviewed efficacy summary in this indication
VotoplamPhase 3Small moleculeHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
Ifezuntirgene InilparvovecPhase 1/2Gene therapy / editingHuntingtin (HTT) genenot yet gradedNo reviewed efficacy summary in this indication
WVE-003Phase 1/2RNA / oligonucleotideHuntingtin (HTT)Weak signal
NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results).
BrezosiranPhase 1RNA / oligonucleotideHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
RG6662
—(overall)
Gene therapy / editing—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow tanruprubart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
Phase 3Guillain-Barré SyndromeRecruiting
Est. primary completion 2027-05-31 · NCT07020819 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 January 2026Filing submittedMarketing authorisation application submitted to the EMA for tanruprubart in Guillain-Barré syndrome
EU, EMA · Annexon, Inc. · Source ↗
4 June 2024Topline resultPivotal Phase 3 (NCT04701164) topline: ANX005 30 mg/kg met the primary endpoint (GBS-DS at week 8)
Global · Annexon, Inc. · Source ↗